Spruce Biosciences is no longer the congenital adrenal hyperplasia company that listed five years ago. The equity is now a single-asset filing story built around tralesinidase alfa enzyme replacement therapy, known as TA-ERT, for Sanfilippo syndrome type B. That fatal pediatric neurodegenerative disease still has no approved treatment. Management recast the firm after tildacerfont failed in classic congenital adrenal hyperplasia and after the Japan partner walked away. The investment debate is whether a planned biologics license application later this year converts a cash-heavy microcap into a first commercial rare-disease operator.
Cash nearly doubled after an April underwritten offering that cleared about $64 million net. Mid-year cash sat near $96 million. That raise, stacked on an Avenue Capital term loan with only the first slice funded, is why management now claims runway into the second half of next year. Research spending reaccelerated as manufacturing scale-up and pre-launch hiring replaced the old hormone program. The market is paying a modest premium to net cash for a surrogate-endpoint accelerated-approval shot, not for a diversified pipeline.
The second-quarter operating loss widened because TA-ERT manufacturing and commercial build replaced a prior-year credit that had artificially crushed research expense. Cure Sanfilippo Foundation and the National MPS Society together put just over $5 million into an expanded-access program for children who cannot enter the confirmatory study. The next several months resolve whether the company actually files the application on the stated timetable and whether chemistry and manufacturing batches clear the agency process-validation bar.